Raily Aesthetic Medicine Delays Utilization of Proceeds Amid COVID-19 Challenges

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has provided an update.

Raily Aesthetic Medicine International Holdings Limited announced a delay in utilizing HK$8.6 million of its proceeds intended for organic growth due to challenges in identifying suitable locations in Shanghai during the COVID-19 pandemic. Additionally, HK$7.6 million from the Rights Issue remains unutilized as the company prepares for the registration of aesthetic medical equipment products. The company plans to use these funds by the end of 2025 and March 2026, respectively, and will keep stakeholders informed of any progress.

More about Raily Aesthetic Medicine International Holdings Limited

Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine industry, focusing on providing aesthetic medical services and products. The company aims to expand its presence in China, particularly through establishing aesthetic medical institutions and registering medical equipment products.

Average Trading Volume: 530,727

Technical Sentiment Signal: Sell

Current Market Cap: HK$64.62M

Find detailed analytics on 2135 stock on TipRanks’ Stock Analysis page.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.